The Conversation (0)
Nuvo Pharmaceuticals announced its financial and operational results for their third quarter of the year.
Nuvo Pharmaceuticals (TSX:NRI) announced its financial and operational results for their third quarter of the year.
As quoted in the press release:
Third Quarter 2017 and Business Update
- U.S. prescriptions of Pennsaid 2% were 108,000 in the third quarter of 2017 compared to 103,000 prescriptions in the third quarter of 2016 according to IMS Health. For the first nine months of 2017, U.S. prescriptions of Pennsaid 2% were 324,000 compared to 338,000 for the first nine months of 2016.
- In August 2017, the Company announced it had secured a $6.0 million operating revolving credit facility (Facility) with Royal Bank of Canada (RBC). The Facility is a standby Facility that can be drawn by Nuvo for working capital requirements and general corporate purposes. Drawings are limited to a percentage of the Company’s then outstanding accounts receivable and inventory. The Company has not drawn any amount of the Facility.
Click here to read the full press release.
Source: www.newswire.ca
